Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Analyst picks & changes

Amgen Inc.

(AMGN), Thousand Oaks, Calif.

Business: Biopharmaceuticals

Deutsche Bank analyst Dennis Harp raised his price target to $81 from $77 and increased his 2003 and 2004 EPS estimates

Read the full 299 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE